A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma.

Trial Profile

A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Mesna; Pegfilgrastim
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2018.
    • 18 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017, according to ClinicalTrials.gov record.
    • 17 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top